vs

Side-by-side financial comparison of InfuSystem Holdings, Inc (INFU) and SILICOM LTD. (SILC). Click either name above to swap in a different company.

SILICOM LTD. is the larger business by last-quarter revenue ($61.9M vs $36.2M, roughly 1.7× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs 6.6%). InfuSystem Holdings, Inc produced more free cash flow last quarter ($7.0M vs $-3.3M).

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

Silicom Ltd. is a publicly traded company, headquartered in Israel, that specializes in the design, manufacture and marketing of connectivity solutions for a range of servers and server-based systems. Its shares are listed on the NASDAQ Global Market and on the Tel Aviv Stock Exchange. Silicom is a member of the RAD Group family of companies.

INFU vs SILC — Head-to-Head

Bigger by revenue
SILC
SILC
1.7× larger
SILC
$61.9M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+0.5% gap
INFU
7.0%
6.6%
SILC
More free cash flow
INFU
INFU
$10.3M more FCF
INFU
$7.0M
$-3.3M
SILC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INFU
INFU
SILC
SILC
Revenue
$36.2M
$61.9M
Net Profit
$-11.5M
Gross Margin
56.4%
30.6%
Operating Margin
10.3%
-19.8%
Net Margin
-18.5%
Revenue YoY
7.0%
6.6%
Net Profit YoY
16.3%
EPS (diluted)
$0.09
$-2.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INFU
INFU
SILC
SILC
Q4 25
$36.2M
$61.9M
Q3 25
$36.5M
Q2 25
$36.0M
Q1 25
$34.7M
Q4 24
$33.8M
$58.1M
Q3 24
$35.3M
Q2 24
$33.7M
Q1 24
$32.0M
Net Profit
INFU
INFU
SILC
SILC
Q4 25
$-11.5M
Q3 25
$2.3M
Q2 25
$2.6M
Q1 25
$-267.0K
Q4 24
$-13.7M
Q3 24
$1.8M
Q2 24
$717.0K
Q1 24
$-1.1M
Gross Margin
INFU
INFU
SILC
SILC
Q4 25
56.4%
30.6%
Q3 25
57.1%
Q2 25
55.2%
Q1 25
55.2%
Q4 24
53.8%
28.6%
Q3 24
53.9%
Q2 24
49.5%
Q1 24
51.5%
Operating Margin
INFU
INFU
SILC
SILC
Q4 25
10.3%
-19.8%
Q3 25
10.4%
Q2 25
10.5%
Q1 25
1.8%
Q4 24
7.7%
-22.8%
Q3 24
9.2%
Q2 24
5.5%
Q1 24
-2.6%
Net Margin
INFU
INFU
SILC
SILC
Q4 25
-18.5%
Q3 25
6.2%
Q2 25
7.2%
Q1 25
-0.8%
Q4 24
-23.6%
Q3 24
5.1%
Q2 24
2.1%
Q1 24
-3.5%
EPS (diluted)
INFU
INFU
SILC
SILC
Q4 25
$0.09
$-2.01
Q3 25
$0.11
Q2 25
$0.12
Q1 25
$-0.01
Q4 24
$0.05
$-2.28
Q3 24
$0.08
Q2 24
$0.03
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INFU
INFU
SILC
SILC
Cash + ST InvestmentsLiquidity on hand
$3.2M
$42.1M
Total DebtLower is stronger
$19.6M
Stockholders' EquityBook value
$57.3M
$117.5M
Total Assets
$100.6M
$152.2M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INFU
INFU
SILC
SILC
Q4 25
$3.2M
$42.1M
Q3 25
$955.0K
Q2 25
$720.0K
Q1 25
$1.5M
Q4 24
$527.0K
$72.1M
Q3 24
$380.0K
Q2 24
$146.0K
Q1 24
$822.0K
Total Debt
INFU
INFU
SILC
SILC
Q4 25
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Q1 24
$29.9M
Stockholders' Equity
INFU
INFU
SILC
SILC
Q4 25
$57.3M
$117.5M
Q3 25
$55.5M
Q2 25
$54.5M
Q1 25
$55.1M
Q4 24
$57.5M
$127.8M
Q3 24
$55.5M
Q2 24
$53.5M
Q1 24
$52.3M
Total Assets
INFU
INFU
SILC
SILC
Q4 25
$100.6M
$152.2M
Q3 25
$98.9M
Q2 25
$100.8M
Q1 25
$104.3M
Q4 24
$103.6M
$150.4M
Q3 24
$105.3M
Q2 24
$108.5M
Q1 24
$104.8M
Debt / Equity
INFU
INFU
SILC
SILC
Q4 25
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×
Q1 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INFU
INFU
SILC
SILC
Operating Cash FlowLast quarter
$7.1M
$-2.2M
Free Cash FlowOCF − Capex
$7.0M
$-3.3M
FCF MarginFCF / Revenue
19.3%
-5.4%
Capex IntensityCapex / Revenue
0.4%
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INFU
INFU
SILC
SILC
Q4 25
$7.1M
$-2.2M
Q3 25
$8.5M
Q2 25
$7.0M
Q1 25
$1.8M
Q4 24
$7.9M
$18.3M
Q3 24
$9.8M
Q2 24
$2.3M
Q1 24
$377.0K
Free Cash Flow
INFU
INFU
SILC
SILC
Q4 25
$7.0M
$-3.3M
Q3 25
$8.4M
Q2 25
$6.8M
Q1 25
$1.6M
Q4 24
$7.4M
$17.4M
Q3 24
$9.8M
Q2 24
$2.0M
Q1 24
$195.0K
FCF Margin
INFU
INFU
SILC
SILC
Q4 25
19.3%
-5.4%
Q3 25
23.1%
Q2 25
18.9%
Q1 25
4.7%
Q4 24
21.9%
29.9%
Q3 24
27.7%
Q2 24
5.9%
Q1 24
0.6%
Capex Intensity
INFU
INFU
SILC
SILC
Q4 25
0.4%
1.9%
Q3 25
0.2%
Q2 25
0.6%
Q1 25
0.4%
Q4 24
1.6%
1.6%
Q3 24
0.1%
Q2 24
1.0%
Q1 24
0.6%
Cash Conversion
INFU
INFU
SILC
SILC
Q4 25
Q3 25
3.76×
Q2 25
2.70×
Q1 25
Q4 24
Q3 24
5.45×
Q2 24
3.22×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

SILC
SILC

Segment breakdown not available.

Related Comparisons